International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 779-785 doi: 10.5281/zenodo.16901752
Original Article
Diagnostic and Prognostic Relevance of Ceruloplasmin, Transferrin, and High-Sensitivity C-Reactive Protein in Type 2 Diabetes Mellitus: A Case-Control Study
 ,
 ,
Published
Aug. 19, 2025
Abstract

Background:
Type 2 diabetes mellitus (T2DM) is associated with chronic low-grade inflammation and oxidative stress. Biomarkers like ceruloplasmin, transferrin, and high-sensitivity C-reactive protein (hs-CRP) may offer diagnostic and prognostic value.

Objectives:
To evaluate serum levels of ceruloplasmin, transferrin, and hs-CRP in T2DM patients and analyze their correlation with glycemic parameters.

Methods:
A case-control observational study was conducted with 130 T2DM patients and 60 age- and sex-matched healthy controls. Fasting blood samples were analyzed for hs-CRP, ceruloplasmin, transferrin, fasting glucose, and HbA1c. Statistical analysis included unpaired t-tests, Pearson correlation, and ROC curve analysis.

Results:
T2DM patients showed significantly elevated hs-CRP (p<0.001) and ceruloplasmin (p<0.01), and decreased transferrin levels (p<0.01) compared to controls. hs-CRP and ceruloplasmin positively correlated with HbA1c and fasting blood glucose, while transferrin showed an inverse correlation. ROC analysis demonstrated hs-CRP had the highest diagnostic accuracy (AUC: 0.84), followed by ceruloplasmin (0.77) and transferrin (0.71).

Conclusion:
hs-CRP, ceruloplasmin, and transferrin serve as accessible, cost-effective biomarkers reflecting inflammatory and oxidative stress status in T2DM. Their correlation with glycemic parameters underscores their potential utility in monitoring disease progression and risk stratification.

 

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
62 Views
178 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved